<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ecodag</journal-id><journal-title-group><journal-title xml:lang="ru">Юг России: экология, развитие</journal-title><trans-title-group xml:lang="en"><trans-title>South of Russia: ecology, development</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1992-1098</issn><issn pub-type="epub">2413-0958</issn><publisher><publisher-name>State Institute of Applied Ecology of the Republic of Dagestan</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18470/1992-1098-2024-1-4</article-id><article-id custom-type="elpub" pub-id-type="custom">ecodag-3063</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ВИРУСОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>VIROLOGY</subject></subj-group></article-categories><title-group><article-title>Генетическое разнообразие вируса гепатита С и распространенность мутаций резистентности к ингибиторам NS5А в Красноярском крае</article-title><trans-title-group xml:lang="en"><trans-title>Genetic diversity of hepatitis C virus and the prevalence of resistance mutations to NS5A inhibitors in the Krasnoyarsk region</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0465-1260</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Екушов</surname><given-names>В. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Ekushov</surname><given-names>V. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Василий Е. Екушов - младший научный сотрудник.</p><p>630559 Новосибирская область, Новосибирск, рп. Кольцово. Тел. +79134706331</p></bio><bio xml:lang="en"><p>Vasily E. Ekushov - Junior Researcher, Vector State Research Centre of Virology and Biotechnology Koltsovo</p><p>Novosibirsk, Novosibirskiy region, 630559. Tel. +79134706331</p></bio><email xlink:type="simple">Treijd460297@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7418-4872</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тотменин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Totmenin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алексей В. Тотменин</p><p>Кольцово</p></bio><bio xml:lang="en"><p>Koltsovo</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5896-8231</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Готфрид</surname><given-names>Л. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Gotfrid</surname><given-names>L. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Людмила Г. Готфрид</p><p>Кольцово</p></bio><bio xml:lang="en"><p>Koltsovo</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-1765-1909</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Халиков</surname><given-names>М. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Halikov</surname><given-names>M. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Максим Р. Халиков</p><p>Кольцово</p></bio><bio xml:lang="en"><p>Koltsovo</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-7258-3619</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Миниханова</surname><given-names>В.-В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Minikhanova</surname><given-names>V.-V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Виталла‐Виктория В. Миниханова</p><p>Красноярск</p></bio><bio xml:lang="en"><p>Krasnoyarsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-3265-1778</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скударнов</surname><given-names>С. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Skudarnov</surname><given-names>S. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Е. Скударнов</p><p>Красноярск</p></bio><bio xml:lang="en"><p>Krasnoyarsk</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-4193-6680</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Остапова</surname><given-names>Т. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostapova</surname><given-names>T. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна С. Остапова</p><p>Красноярск</p></bio><bio xml:lang="en"><p>Krasnoyarsk</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0891-0880</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гашникова</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Gashnikova</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья М. Гашникова</p><p>Кольцово</p></bio><bio xml:lang="en"><p>Koltsovo</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Государственный научный центр вирусологии и биотехнологии «Вектор» Роспотребнадзора<country>Россия</country></aff><aff xml:lang="en">Vector State Research Centre of Virology and Biotechnology, Rospotrebnadzor<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Красноярский краевой Центр профилактики и борьбы со СПИД<country>Россия</country></aff><aff xml:lang="en">Krasnoyarsk Regional Centre for Prevention and Control of AIDS<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">Виталла‐Виктория В. Миниханова&#13;
Красноярск<country>Россия</country></aff><aff xml:lang="en">Krasnoyarsk Regional Centre for Prevention and Control of AIDS<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>07</day><month>04</month><year>2024</year></pub-date><volume>19</volume><issue>1</issue><fpage>47</fpage><lpage>59</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Екушов В.Е., Тотменин А.В., Готфрид Л.Г., Халиков М.Р., Миниханова В.В., Скударнов С.Е., Остапова Т.С., Гашникова Н.М., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Екушов В.Е., Тотменин А.В., Готфрид Л.Г., Халиков М.Р., Миниханова В.В., Скударнов С.Е., Остапова Т.С., Гашникова Н.М.</copyright-holder><copyright-holder xml:lang="en">Ekushov V.E., Totmenin A.V., Gotfrid L.G., Halikov M.R., Minikhanova V.V., Skudarnov S.E., Ostapova T.S., Gashnikova N.M.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://ecodag.elpub.ru/ugro/article/view/3063">https://ecodag.elpub.ru/ugro/article/view/3063</self-uri><abstract><p>Цель – исследовать молекулярно‐генетические особенности популяции ВГС, циркулирующей среди ВИЧ‐инфицированных жителей Красноярского края, включая анализ мутаций вируса, связанных с резистентностью к ингибиторам NS5А. Из 94 образцов плазмы крови ВИЧ/ВГС‐инфицированных жителей края выделена суммарная РНК, получены и расшифрованы нуклеотидные последовательности областей гена Core/E1 и гена NS5А, которые использовали для генотипирования и поиска мутаций резистентности.</p><p>В изученной выборке ВГС зарегистрирована циркуляция пяти субтипов вируса: 1b (47,9 %), 3a (37,2 %), 1a (10,6 %), 2a (3,2 %) и 2k (1,1 %). Филогенетический анализ ВГС выявил частичную кластеризацию внутри субтипов 1а и 3a по территориальному принципу. ВГС субтипа 1b, 2а и 2k группировались с другими ВГС, выделенными ранее в России, Армении и Кыргызстане. Среди исследованных ВГС не было найдено кластеров, общих для ВИЧ‐инфицированных лиц с одним путем заражения. Среди пациентов, не имевших опыта приема ПППД, мутации резистентности ВГС в области NS5A для лиц, инфицированных вирусом субтипа 3a, были обнаружены у 42,3 % случаев, для инфицированных ВГС субтипа 1b – в 75,6 % случаев.</p><p>Выполненный анализ разнообразия и встречаемости мутаций лекарственной устойчивости ВГС к препаратам прямого противовирусного действия крайне важен для разработки тактики эффективного лечения ХГС. Высокий уровень распространенности полиморфных мутаций, влияющих на чувствительность к ПППД, указывает на актуальность внедрения анализа резистентности ВГС в клиническую практику.</p></abstract><trans-abstract xml:lang="en"><p>To research the molecular genetic characteristics of the HCV population circulating among HIV‐infected residents of the Krasnoyarsk Territory, including analysis of resistance‐associated mutations to NS5A inhibitors. Total RNA was isolated from 94 blood plasma samples from HIV/HCVinfected residents of the region and the nucleotide sequences of the Core/E1 gene and NS5A gene regions were obtained and deciphered, which were used for genotyping and searching for resistance mutations.</p><p>In the HCV samples studied, the circulation of five virus subtypes was recorded: 1b (47,9 %), 3a (37,2 %), 1a (10,6 %), 2a (3,2 %) and 2k (1,1 %). Phylogenetic analysis of HCVs revealed partial clustering within subtypes 1a and 3a on a territorial basis. HCV subtypes 1b, 2a and 2k were grouped with other HCVs previously isolated in Russia, Armenia and Kyrgyzstan. Among the HCVs studied, no clusters were found that were common to HIV‐infected individuals with the same route of infection. Among patients who had no experience of taking DAAs, HCV resistance mutations in the NS5A region were found in 42,3 % of cases for those infected with subtype 3a virus and in 75,6 % of cases for those infected with HCV subtype 1b.</p><p>The analysis of the diversity and occurrence of mutations of HCV drug resistance to direct antiviral drugs is extremely important for the development of tactics for effective treatment of CHC. The high prevalence of polymorphic mutations that affect sensitivity to DAAs indicates the relevance of introducing HCV resistance analysis into clinical practice.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ВГС</kwd><kwd>генотипы ВГС</kwd><kwd>резистентность ВГС</kwd><kwd>мутации лекарственной устойчивости</kwd><kwd>NS5A</kwd><kwd>ПППД</kwd><kwd>генетический полиморфизм</kwd></kwd-group><kwd-group xml:lang="en"><kwd>HCV</kwd><kwd>Hepatitis C subtypes</kwd><kwd>RASs</kwd><kwd>NS5A</kwd><kwd>DAAs</kwd><kwd>genetic polymorphism</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Исследование проведено в рамках реализации распоряжения Правительства Российской Федерации от 02.04.2022 № 735‐р.</funding-statement></funding-group><funding-group xml:lang="en"><funding-statement>The study was conducted in the framework of the Order of the Government of the Russian Federation dated 02 April 2022 No. 735‐р.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bertino G., et al. Chronic hepatitis C: This and the new era of treatment // World journal of hepatology. 2016. V. 8. N 2. P. 92. DOI: 10.4254/wjh.v8.i2.92</mixed-citation><mixed-citation xml:lang="en">Bertino G., et al. Chronic hepatitis C: This and the new era of treatment. World journal of hepatology, 2016, vol. 8, no. 2, p. 92. DOI: 10.4254/wjh.v8.i2.92</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Dubuisson J. Hepatitis C virus proteins // World journal of gastroenterology: WJG. 2007. V. 13. N 17. P. 2406. DOI: 10.3748/wjg.v13.i17.2406</mixed-citation><mixed-citation xml:lang="en">Dubuisson J. Hepatitis C virus proteins. World journal of gastroenterology: WJG, 2007, vol. 13, no. 17, p. 2406. DOI: 10.3748/wjg.v13.i17.2406</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Schulze zur Wiesch J., et al. The proteins of the Hepatitis C virus: Their features and interactions with intracellular protein phosphorylation // Archives of virology. 2003. V. 148. P. 1247–1267. DOI: 10.1007/s00705‐003‐0115‐8</mixed-citation><mixed-citation xml:lang="en">Schulze zur Wiesch J., et al. The proteins of the Hepatitis C virus: Their features and interactions with intracellular protein phosphorylation. Archives of virology, 2003, vol. 148, pp. 1247–1267. DOI: 10.1007/s00705‐003‐0115‐8</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Simmonds P. Genetic diversity and evolution of hepatitis C virus–15 years on // Journal of General Virology. 2004. V. 85. N 11. P. 3173–3188. DOI: 10.1099/vir.0.80401‐0</mixed-citation><mixed-citation xml:lang="en">Simmonds P. Genetic diversity and evolution of hepatitis C virus–15 years on. Journal of General Virology, 2004, vol. 85, no. 11, pp. 3173–3188. DOI: 10.1099/vir.0.80401‐0</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Correction Naghavi M., et al. Global, regional, and national age‐sex specific all‐cause and cause‐specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // The Lancet. 2015. V. 38. N 9963. P. 117–171. DOI: 10.1016/S0140‐6736(14)61682‐2</mixed-citation><mixed-citation xml:lang="en">Correction Naghavi M. et al. Global, regional, and national age‐sex specific all‐cause and cause‐specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet, 2015, vol. 385, no. 9963, pp. 117–171. DOI: 10.1016/S0140‐6736(14)61682‐2</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Thursz M., Fontanet A. HCV transmission in industrialized countries and resource‐constrained areas // Nature reviews Gastroenterology &amp; hepatology. 2014. V. 11. N 1. P. 28–35. DOI: 10.1038/nrgastro.2013.179</mixed-citation><mixed-citation xml:lang="en">Thursz M., Fontanet A. HCV transmission in industrialized countries and resource‐constrained areas. Nature reviews Gastroenterology &amp; hepatology, 2014, vol. 11, no. 1, pp. 28–35. DOI: 10.1038/nrgastro.2013.179</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pawlotsky J.M., Chevaliez S., McHutchison J.G. The hepatitis C virus life cycle as a target for new antiviral therapies // Gastroenterology. 2007. V. 132. N 5. P. 1979– 1998. DOI: 10.1053/j.gastro.2007.03.116</mixed-citation><mixed-citation xml:lang="en">Pawlotsky J.M., Chevaliez S., McHutchison J.G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology, 2007, vol. 132, no. 5, pp. 1979–1998. DOI: 10.1053/j.gastro.2007.03.116</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hassany M., Elsharkawy A. HCV treatment failure in the Era of DAAs // INTECH open science. 2017. P. 117–129. DOI: 10.5772/67149</mixed-citation><mixed-citation xml:lang="en">Hassany M., Elsharkawy A. HCV treatment failure in the Era of DAAs. INTECH open science, 2017, pp. 117–129. DOI: 10.5772/67149</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Svarovskaia E.S., et al. Infrequent development of resistance in genotype 1–6 hepatitis C virus–infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials // Clinical Infectious Diseases. 2014. V. 59. N 12 P. 1666–1674. DOI: 10.1093/cid/ciu697</mixed-citation><mixed-citation xml:lang="en">Svarovskaia E.S., et al. Infrequent development of resistance in genotype 1–6 hepatitis C virus–infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clinical Infectious Diseases, 2014, vol. 59, no. 12, pp. 1666–1674. DOI: 10.1093/cid/ciu697</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wyles D., et al. Post‐treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir // Journal of hepatology. 2017. V. 66. N 4. P. 703–710. DOI: 10.1016/j.jhep.2016.11.022</mixed-citation><mixed-citation xml:lang="en">Wyles D., et al. Post‐treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. Journal of hepatology, 2017, vol. 66, no. 4, pp. 703–710. DOI: 10.1016/j.jhep.2016.11.022</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wyles D.L., Luetkemeyer A.F. Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens // Topics in antiviral medicine. 2017. V. 25. N 3. P. 103. PMID: 28820725</mixed-citation><mixed-citation xml:lang="en">Wyles D.L., Luetkemeyer A.F. Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens. Topics in antiviral medicine. 2017, vol. 25, no. 3, p. 103. PMID: 28820725</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Pawlotsky J.M. NS5A inhibitors in the treatment of hepatitis C // Journal of hepatology. 2013. V. 59. N 2. P. 375–382. DOI: 10.1016/j.jhep.2013.03.030</mixed-citation><mixed-citation xml:lang="en">Pawlotsky J.M. NS5A inhibitors in the treatment of hepatitis C. Journal of hepatology, 2013, vol. 59, no. 2, pp. 375–382. DOI: 10.1016/j.jhep.2013.03.030</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Jimmerson L.C. The clinical pharmacology of ribavirin: intracellular effects on endogenous nucleotides and hemolytic anemia: diss. University of Colorado Denver, Anschutz Medical Campus. 2016.</mixed-citation><mixed-citation xml:lang="en">Jimmerson L. C. The clinical pharmacology of ribavirin: intracellular effects on endogenous nucleotides and hemolytic anemia: diss. University of Colorado Denver, Anschutz Medical Campus, 2016.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hernandez D., et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors // Journal of Clinical Virology. 2013. V. 57. N 1. P. 13–18. DOI: 10.1016/j.jcv.2012.12.020</mixed-citation><mixed-citation xml:lang="en">Hernandez D., et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. Journal of Clinical Virology, 2013, vol. 57, no. 1, pp. 13–18. DOI: 10.1016/j.jcv.2012.12.020</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Krishnan P., et al. Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with paritaprevir‐ritonavir and ombitasvir // Antimicrobial agents and chemotherapy. 2016. V. 60. N 2. P. 1106–1113. DOI: 10.1128/aac.02606‐15</mixed-citation><mixed-citation xml:lang="en">Krishnan P., et al. Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with paritaprevir‐ritonavir and ombitasvir. Antimicrobial agents and chemotherapy, 2016, vol. 60, no. 2, pp. 1106–113. DOI: 10.1128/aac.02606‐15</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Trickey A., et al. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection: web annex 4: modelling analyses // World Health Organization. 2018. N. WHO/CDS/HIV/18.38.</mixed-citation><mixed-citation xml:lang="en">Trickey A., et al. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection: web annex 4: modelling analyses. World Health Organization. 2018, no. WHO/CDS/HIV/18.38.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tamura K., Stecher G., Kumar S. MEGA11: molecular evolutionary genetics analysis version 11 // Molecular biology and evolution. 2021. V. 38. N 7. P. 3022–3027. DOI: 10.1093/molbev/msab120</mixed-citation><mixed-citation xml:lang="en">Tamura K., Stecher G., Kumar S. MEGA11: molecular evolutionary genetics analysis version 11. Molecular biology and evolution, 2021, vol. 38, no. 7, pp. 3022–3027. DOI: 10.1093/molbev/msab120</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Larsson A. AliView: a fast and lightweight alignment viewer and editor for large datasets // Bioinformatics. 2014. V. 30. N 22. P. 3276–3278. DOI: 10.1093/bioinformatics/btu531</mixed-citation><mixed-citation xml:lang="en">Larsson A. AliView: a fast and lightweight alignment viewer and editor for large datasets. Bioinformatics, 2014, vol. 30, no. 22, pp. 3276–3278. DOI: 10.1093/bioinformatics/btu531</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Katoh K., Rozewicki J., Yamada K.D. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization // Briefings in bioinformatics. 2019. V. 20. N 4. P. 1160–1166. DOI: 10.1093/bib/bbx108</mixed-citation><mixed-citation xml:lang="en">Katoh K., Rozewicki J., Yamada K.D. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. Briefings in bioinformatics, 2019, vol. 20, no. 4, pp. 1160–1166. DOI: 10.1093/bib/bbx108</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">von Haeseler A., et al. IQ‐TREE: A fast and effective stochastic algorithm for estimating maximum‐likelihood phylogenies // Molecular Biology and Evolution. 2014. V. 32. Iss. 1. P. 268–274. DOI: 10.1093/molbev/msu300</mixed-citation><mixed-citation xml:lang="en">von Haeseler A., et al. IQ‐TREE: A fast and effective stochastic algorithm for estimating maximum‐likelihood phylogenies. Molecular Biology and Evolution, 2014, vol. 32, iss. 1, pp. 268–274. DOI: 10.1093/molbev/msu300</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Singer J.B., et al. GLUE: a flexible software system for virus sequence data // BMC bioinformatics. 2018. V. 19. P. 1–18. DOI: 10.1186/s12859‐018‐2459‐9</mixed-citation><mixed-citation xml:lang="en">Singer J.B., et al. GLUE: a flexible software system for virus sequence data. BMC bioinformatics, 2018, vol. 19, pp. 1–18. DOI: 10.1186/s12859‐018‐2459‐9</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Singer J.B., et al. Interpreting viral deep sequencing data with GLUE // Viruses. 2019. V. 11. N 4. P. 323. DOI: 10.3390/v11040323</mixed-citation><mixed-citation xml:lang="en">Singer J.B., et al. Interpreting viral deep sequencing data with GLUE. Viruses, 2019, vol. 11, no. 4, p. 323. DOI: 10.3390/v11040323</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Кашникова А.Д. и др. Молекулярно‐генетический мониторинг как компонент эпидемиологического надзора за гепатитом С // Здоровье населения и среда обитания. 2022. Т. 30. N 11. С. 76–81. DOI: 10.35627/2219‐5238/2022‐30‐11‐76‐81</mixed-citation><mixed-citation xml:lang="en">Kashnikova A.D., et al. Genetic monitoring as a component of hepatitis C superveillance. The Russian journal Public Health and Life Environment, 2022, vol. 30, no. 11, pp. 76–81. (In Russian) DOI: 10.35627/22195238/2022‐30‐11‐76‐81</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Кочнева Г.В. и др. О возможности искоренения гепатита C в России // Молекулярная генетика, микробиология и вирусология. 2021. Т. 39. N 1. С. 31–41. DOI: 10.17116/molgen20213901131</mixed-citation><mixed-citation xml:lang="en">Kochneva G.V., et al. On the possibility of eradicating hepatitis C in Russia. Molecular Genetics, Microbiology and Virology, 2021, vol. 39, no. 1, pp. 31–41. (In Russian) DOI: 10.17116/molgen20213901131</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Базыкина Е.А. и др. Оценка эпидемиологических особенностей ВИЧ‐инфекции и генотипического разнообразия вируса гепатита С у ВИЧ‐инфицированных граждан в субъектах Дальневосточного федерального округа // Эпидемиология и вакцинопрофилактика. 2021. Т. 20. N 5. С. 79–88. DOI: 10.31631/2073‐3046‐2021‐20‐579‐88</mixed-citation><mixed-citation xml:lang="en">Bazykina E.A., et al. Distribution of Hepatitis C Virus among People Living with HIV in Constituent Entities of the Far Eastern Federal District. Epidemiology and Vaccinal Prevention, 2021, vol. 20, no. 5, pp. 79–88. (In Russian) DOI: 10.31631/2073‐3046‐2021‐20‐5‐79‐88</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Котова В.О. и др. Генетическое разнообразие вируса гепатита С среди населения Нанайского района Хабаровского края // Инфекция и иммунитет. 2021. Т. 11. N 1. С. 148–156. DOI: 10.15789/2220‐7619‐GDO‐1265</mixed-citation><mixed-citation xml:lang="en">Kotova V.O., et al. Genetic diversity of hepatitis C virus in Nanaian region, Khabarovsk territory. Russian Journal of Infection and Immunity, 2021, vol. 11, no. 1, pp. 148–156. (In Russian) DOI: 10.15789/2220‐7619‐GDO‐1265</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Pawlotsky J.M., et al. EASL recommendations on treatment of hepatitis C 2018 // Journal of hepatology. 2018. V. 69. N 2. P. 461–511. DOI: 10.1016/j.jhep.2018.03.026</mixed-citation><mixed-citation xml:lang="en">Pawlotsky J.M., et al. EASL recommendations on treatment of hepatitis C 2018. Journal of hepatology, 2018, vol. 69, no. 2, pp. 461–511. DOI: 10.1016/j.jhep.2018.03.026</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Lahser F., et al. Interim analysis of a 3‐year follow‐up study of NS5A and NS3 resistance‐associated substitutions after treatment with grazoprevir‐containing regimens in participants with chronic HCV infection // Antiviral therapy. 2018. V. 23. N 7. P. 593–603. DOI: 10.3851/IMP3253</mixed-citation><mixed-citation xml:lang="en">Lahser F., et al. Interim analysis of a 3‐year follow‐up study of NS5A and NS3 resistance‐associated substitutions after treatment with grazoprevir‐containing regimens in participants with chronic HCV infection. Antiviral therapy, 2018, vol. 23, no. 7, pp. 593–603. DOI: 10.3851/IMP3253</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Krishnan P., et al. O057: Long‐term follow‐up of treatment‐emergent resistance‐associated variants in NS3, NS5A and NS5B with paritaprevir/r‐, ombitasvir‐and dasabuvir‐based regimens // Journal of hepatology. 2015. V. 62. P. S220. DOI: 10.1016/S0168‐8278(15)30071‐4</mixed-citation><mixed-citation xml:lang="en">Krishnan P., et al. O057: Long‐term follow‐up of treatment‐emergent resistance‐associated variants in NS3, NS5A and NS5B with paritaprevir/r‐, ombitasvir‐and dasabuvir‐based regimens. Journal of hepatology, 2015, vol. 62, p. S220. DOI: 10.1016/S0168‐8278(15)30071‐4</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Wyles D., et al. Long‐term persistence of HCV NS5A resistance‐associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir // Antiviral therapy. 2018. V. 23. N 3. P. 229–238. DOI: 10.3851/IMP3181</mixed-citation><mixed-citation xml:lang="en">Wyles D., et al. Long‐term persistence of HCV NS5A resistance‐associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antiviral therapy, 2018, vol. 23, no. 3, pp. 229–238. DOI: 10.3851/IMP3181</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Mawatari S., et al. New resistance‐associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir // Journal of gastroenterology. 2017. V. 52. P. 855–867. DOI: 10.1007/s00535‐016‐1303‐0</mixed-citation><mixed-citation xml:lang="en">Mawatari S., et al. New resistance‐associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir. Journal of gastroenterology, 2017, vol. 52, pp. 855–867. DOI: 10.1007/s00535‐0161303‐0</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez Luis B.A., et al. Baseline hepatitis C virus NS5A resistance‐associated polymorphisms in patients with and without human immunodeficiency virus coinfection in Mexico // Microbial Drug Resistance. 2021. V. 27. N 9. P. 1195–1202. DOI: 10.1089/mdr.2020.0436</mixed-citation><mixed-citation xml:lang="en">Lopez Luis B.A., et al. Baseline hepatitis C virus NS5A resistance‐associated polymorphisms in patients with and without human immunodeficiency virus coinfection in Mexico. Microbial Drug Resistance, 2021, vol. 27, no. 9, pp. 1195–1202. DOI: 10.1089/mdr.2020.0436</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Seronello S., et al. Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals // PLoS One. 2011. V. 6. N 11. Article id: e27436. DOI: 10.1371/journal.pone.0027436</mixed-citation><mixed-citation xml:lang="en">Seronello S., et al. Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals. PLoS One, 2011, vol. 6, no. 11, article id: e27436. DOI: 10.1371/journal.pone.0027436</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Wyles D.L., et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV‐1 // New England Journal of Medicine. 2015. V. 373. N 8. P. 714–725. DOI: 10.1056/NEJMoa1503153</mixed-citation><mixed-citation xml:lang="en">Wyles D.L., et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV‐1. New England Journal of Medicine, 2015, vol. 373, no. 8, pp. 714–725. DOI: 10.1056/NEJMoa1503153</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Nelson D.R., et al. All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study // Hepatology. 2015. V. 61. N 4. P. 1127–1135. DOI: 10.1002/hep.27726</mixed-citation><mixed-citation xml:lang="en">Nelson D.R., et al. All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study. Hepatology, 2015, vol. 61, no. 4, pp. 1127–1135. DOI: 10.1002/hep.27726</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Liu R., et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir // Antimicrobial agents and chemotherapy. 2015. V. 59. N 11. P. 6922–6929. DOI: 10.1128/aac.01390‐15</mixed-citation><mixed-citation xml:lang="en">Liu R., et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrobial agents and chemotherapy, 2015, vol. 59, no. 11, pp. 6922–6929. DOI: 10.1128/aac.01390‐15</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Poordad F., et al. High antiviral activity of NS 5A inhibitor ABT‐530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection // Liver International. 2016. V. 36. N 8. P. 1125–1132. DOI: 10.1111/liv.13067</mixed-citation><mixed-citation xml:lang="en">Poordad F., et al. High antiviral activity of NS 5A inhibitor ABT‐530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver International, 2016, vol. 36, no. 8, pp. 1125–1132. DOI: 10.1111/liv.13067</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Hezode C., et al. Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies // Journal of hepatology. 2018. V. 68. N 5. P. 895–903. DOI: 10.1016/j.jhep.2017.11.032</mixed-citation><mixed-citation xml:lang="en">Hezode C., et al. Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. Journal of hepatology, 2018, vol. 68, no. 5, pp. 895–903. DOI: 10.1016/j.jhep.2017.11.032</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Cabral B.C.A., et al. Frequency distribution of HCV resistance‐associated variants in infected patients treated with direct‐acting antivirals // International Journal of Infectious Diseases. 2022. V. 115. P. 171–177. DOI: 10.1016/j.ijid.2021.12.320</mixed-citation><mixed-citation xml:lang="en">Cabral B.C.A., et al. Frequency distribution of HCV resistance‐associated variants in infected patients treated with direct‐acting antivirals. International Journal of Infectious Diseases, 2022, vol. 115, pp. 171–177. DOI: 10.1016/j.ijid.2021.12.320</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Zeuzem S., et al. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection // Journal of hepatology. 2016. V. 64. N 2. P. 292–300. DOI: 10.1016/j.jhep.2015.09.024</mixed-citation><mixed-citation xml:lang="en">Zeuzem S., et al. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. Journal of hepatology, 2016, vol. 64, no. 2, pp. 292–300. DOI: 10.1016/j.jhep.2015.09.024</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Curry M.P., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis // New England Journal of Medicine. 2015. V. 373. N 27. P. 2618–2628. DOI: 10.1056/NEJMoa1512614</mixed-citation><mixed-citation xml:lang="en">Curry M.P., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. New England Journal of Medicine, 2015, vol. 373, no. 27, pp. 2618–2628. DOI: 10.1056/NEJMoa1512614</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Gottwein J.M., et al. Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1–7 and escape variants // Gastroenterology. 2018. V. 154. N 5. P. 1435–1448. DOI: 10.1053/j.gastro.2017.12.015</mixed-citation><mixed-citation xml:lang="en">Gottwein J.M., et al. Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1–7 and escape variants. Gastroenterology, 2018, vol. 154, no. 5, pp. 1435–1448. DOI: 10.1053/j.gastro.2017.12.015</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Krishnan P., et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A // Antimicrobial agents and chemotherapy. 2015. V. 59. N 2. P. 979–987. DOI: 10.1128/aac.04226‐14</mixed-citation><mixed-citation xml:lang="en">Krishnan P., et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrobial agents and chemotherapy, 2015, vol. 59, no. 2, pp. 979–987. DOI: 10.1128/aac.04226‐14</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Nakamoto S., et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations // World journal of gastroenterology: WJG. 2014. V. 20. N 11. P. 2902. DOI: 10.3748/wjg.v20.i11.2902</mixed-citation><mixed-citation xml:lang="en">Nakamoto S., et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World journal of gastroenterology: WJG, 2014, vol. 20, no. 11, p. 2902. DOI: 10.3748/wjg.v20.i11.2902</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Uchida Y., et al. Development of rare resistance‐associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two‐hit mechanism // Hepatology Research. 2016. V. 46. N 12. P. 1234–1246. DOI: 10.1111/hepr.12673</mixed-citation><mixed-citation xml:lang="en">Uchida Y., et al. Development of rare resistance‐associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two‐hit mechanism. Hepatology Research, 2016, vol. 46, no. 12, pp. 1234–1246. DOI: 10.1111/hepr.12673</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Uchida Y., et al. “Reversi‐type virologic failure” involved in the development of non‐structural protein 5A resistance‐associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline // Hepatology Research. 2017. V. 47. N 13. P. 1397–1407. DOI: 10.1111/hepr.12882</mixed-citation><mixed-citation xml:lang="en">Uchida Y., et al. “Reversi‐type virologic failure” involved in the development of non‐structural protein 5A resistance‐associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatology Research, 2017, vol. 47, no. 13, pp. 1397–1407. DOI: 10.1111/hepr.12882</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Kwo P., et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatmentexperienced patients with chronic hepatitis C infection // Gastroenterology. 2017. V. 152. N 1. P. 164–175. DOI: 10.1053/j.gastro.2016.09.045</mixed-citation><mixed-citation xml:lang="en">Kwo P., et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatmentexperienced patients with chronic hepatitis C infection. Gastroenterology, 2017, vol. 152, no. 1, pp. 164–175. DOI: 10.1053/j.gastro.2016.09.045</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Fourati S., et al. Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS 5A inhibitor // Alimentary pharmacology &amp; therapeutics. 2018. V. 47. N 5. P. 665–673. DOI: 10.1111/apt.14478</mixed-citation><mixed-citation xml:lang="en">Fourati S., et al. Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS 5A inhibitor. Alimentary pharmacology &amp; therapeutics, 2018, vol. 47, no. 5, pp. 665–673. DOI: 10.1111/apt.14478</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Pelosi L.A., et al. Effect on hepatitis C virus replication of combinations of direct‐acting antivirals, including NS5A inhibitor daclatasvir // Antimicrobial agents and chemotherapy. 2012. V. 56. N 10. P. 5230–5239. DOI: 10.1128/aac.01209‐12</mixed-citation><mixed-citation xml:lang="en">Pelosi L.A., et al. Effect on hepatitis C virus replication of combinations of direct‐acting antivirals, including NS5A inhibitor daclatasvir. Antimicrobial agents and chemotherapy, 2012, vol. 56, no. 10, pp. 5230–5239. DOI: 10.1128/aac.01209‐12</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Kumada H., et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study // Journal of gastroenterology. 2017. V. 52. P. 520–533. DOI: 10.1007/s00535‐016‐1285‐y</mixed-citation><mixed-citation xml:lang="en">Kumada H., et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. Journal of gastroenterology, 2017, vol. 52, pp. 520–533. DOI: 10.1007/s00535‐016‐1285‐y</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Kozuka R., et al. The presence of multiple NS 5A RAS s is associated with the outcome of sofosbuvir and ledipasvir therapy in NS 5A inhibitor‐naïve patients with chronic HCV genotype 1b infection in a real‐world cohort // Journal of Viral Hepatitis. 2018. V. 25. N 5. P. 535–542. DOI: 10.1111/jvh.12850</mixed-citation><mixed-citation xml:lang="en">Kozuka R., et al. The presence of multiple NS 5A RAS s is associated with the outcome of sofosbuvir and ledipasvir therapy in NS 5A inhibitor‐naïve patients with chronic HCV genotype 1b infection in a real‐world cohort. Journal of Viral Hepatitis, 2018, vol. 25, no. 5, pp. 535–542. DOI: 10.1111/jvh.12850</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Kao J.H., et al. All‐oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub‐analysis in Asian patients from the HALLMARK DUAL study // Liver International. 2016. V. 36. N 10. P. 1433– 1441. DOI: 10.1111/liv.13128</mixed-citation><mixed-citation xml:lang="en">Kao J.H., et al. All‐oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub‐analysis in Asian patients from the HALLMARK DUAL study. Liver International, 2016, vol. 36, no. 10, pp. 1433– 1441. DOI: 10.1111/liv.13128</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Dietz J., et al. Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1‐infected patients // PloS one. 2015. V. 10. N 8. Article id: e0134395. DOI: 10.1371/journal.pone.0134395</mixed-citation><mixed-citation xml:lang="en">Dietz J., et al. Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1‐infected patients. PloS one, 2015, vol. 10, no. 8, article id: e0134395. DOI: 10.1371/journal.pone.0134395</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Kwo P.Y., et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis // Journal of hepatology. 2017. V. 67. N 2. P. 263– 271. DOI: 10.1016/j.jhep.2017.03.039</mixed-citation><mixed-citation xml:lang="en">Kwo P.Y., et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. Journal of hepatology, 2017, vol. 67, no. 2, pp. 263–271. DOI: 10.1016/j.jhep.2017.03.039</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Zeuzem S., et al. NS5A resistance‐associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome // Journal of hepatology. 2017. V. 66. N 5. P. 910–918. DOI: 10.1016/j.jhep.2017.01.007</mixed-citation><mixed-citation xml:lang="en">Zeuzem S., et al. NS5A resistance‐associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. Journal of hepatology, 2017, vol. 66, no. 5, pp. 910–918. DOI: 10.1016/j.jhep.2017.01.007</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Рейнгардт Д.Э. и др. Распространенность мутаций лекарственной устойчивости вируса гепатита С среди пациентов с рецидивом заболевания на терапии препаратами прямого противовирусного действия // ВИЧ‐инфекция и иммуносупрессии. 2024. Т. 15. N 4. С. 86–93. DOI: 10.22328/2077‐9828‐2023‐15‐4‐86‐93</mixed-citation><mixed-citation xml:lang="en">Reingardt D.E., et al. Distribution of hepatitis С virus drug resistance mutations among patients with recurrence of the disease during therapy with direct antiviral drugs. HIV Infection and Immunosuppressive, 2024, vol. 15, no. 4, pp. 86–93. (In Russian) DOI: 10.22328/2077‐9828‐2023‐154‐86‐93</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Кичатова В.С. и др. Лекарственно‐резистентные варианты ВГС субтипа 1b, циркулирующие на территории Российской Федерации: анализ аминокислотных мутаций в белках NS5a и core // Журнал инфектологии. 2018. Т. 10. N 4. С. 30–36. DOI: 10.22625/2072‐6732‐2018‐10‐4‐30‐36</mixed-citation><mixed-citation xml:lang="en">Kichatova V.S., et al. Drug resistant variants of hepatitis C virus genotype 1b in Russia: analysis of aminoacid substitutions in NS5a and core proteins. Journal Infectology, 2018, vol. 10, no. 4, pp. 30–36. (In Russian) DOI: 10.22625/2072‐6732‐2018‐10‐4‐30‐36</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Bartels D.J., et al. Hepatitis C virus variants with decreased sensitivity to direct‐acting antivirals (DAAs) were rarely observed in DAA‐naive patients prior to treatment // Journal of virology. 2013. V. 87. N 3. P. 1544–1553. DOI: 10.1128/jvi.02294‐12</mixed-citation><mixed-citation xml:lang="en">Bartels D.J., et al. Hepatitis C virus variants with decreased sensitivity to direct‐acting antivirals (DAAs) were rarely observed in DAA‐naive patients prior to treatment. Journal of virology, 2013, vol. 87, no. 3, pp. 1544–1553. DOI: 10.1128/jvi.02294‐12</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Z., et al. Global prevalence of pre‐existing HCV variants resistant to direct‐acting antiviral agents (DAAs): mining the GenBank HCV genome data // Scientific reports. 2016. V. 6. N 1. Article id: 20310. DOI: 10.1038/srep20310</mixed-citation><mixed-citation xml:lang="en">Chen Z., et al. Global prevalence of pre‐existing HCV variants resistant to direct‐acting antiviral agents (DAAs): mining the GenBank HCV genome data. Scientific reports, 2016, vol. 6, no. 1, article id: 20310. DOI: 10.1038/srep20310</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
